Active Filter(s):
Details:
Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, it reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. It is approved by Health Canada for the treatment of type 2 diabetes.
Lead Product(s): Dapagliflozin
Therapeutic Area: Endocrinology Product Name: Forxiga-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023